Cypherpunk Technologies (CYPH) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
18 Jun, 2026Opening remarks and agenda
Meeting called to order at 11:00 A.M. on June 18th, 2026, with agenda and rules of conduct provided to all stockholders.
Items of business included election of two Class III directors, advisory vote on executive compensation, and ratification of independent auditors.
Introduction of board members, outside counsel, and inspector of election.
Board and executive committee updates
Two Class III directors, Will McEvoy and Nissim Mashiach, were nominated for terms ending in 2029.
Shareholder proposals
Advisory vote on executive compensation for named executive officers presented.
Proposal to ratify EisnerAmper LLP as independent auditors for fiscal year ending December 31, 2026.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Cypherpunk Technologies
- Q2 2026 profit surged on ZEC gains; lead cancer drug advanced to Phase 3 with FDA support.CYPH
Q2 2026 - $77.2M Q1 loss driven by ZEC volatility; Zcash holdings and clinical progress highlighted.CYPH
Q1 2026 - Virtual annual meeting to vote on directors, executive pay, and auditor, with strong governance focus.CYPH
Proxy filing - Virtual annual meeting set for June 18, 2026, with key votes on directors, pay, and auditor.CYPH
Proxy filing - Returned to profitability in 2025 with strong ZEC gains, new capital, and clinical progress.CYPH
Q4 2025 - Shareholders approved key proposals including share increase, reverse split, and new equity plan.CYPH
AGM 2025 - Phase 2 trials for DKN-01 in gastric and colorectal cancer near key data readouts and expansion.CYPH
Piper Sandler 36th Annual Healthcare Conference - Sirexatamab improved response rates in CRC, especially in DKK1-high and VEGF-naive patients.CYPH
Study Result - Sirexatamab shows strong efficacy in GI cancer trials; FL-501 advances toward clinical studies.CYPH
43rd Annual J.P. Morgan Healthcare Conference 2025